- Home
- PSHG vs QNCX Comparison
PSHG vs QNCX Comparison
Compare PSHG & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | QNCX |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 19.9M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PSHG | QNCX |
|---|---|---|
| Price | $1.73 | $1.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.8K | ★ 1.1M |
| Earning Date | 05-26-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $1.59 | ★ $0.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $0.08 |
| 52 Week High | $2.58 | $4.55 |
Technical Indicators
Market Signals| Indicator | PSHG | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 54.16 |
| Support Level | N/A | $0.10 |
| Resistance Level | $2.04 | $1.50 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 10.37 | 5.00 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.